Trial
NCT00567879
A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Breast Cancer
Intervention
Panobinostat
Why stopped
The study was terminated early due to insufficient evidence of clinical benefit.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-05-09